Phenotypic Characterization and Prevalence of Carbapenemase-Producing <i>Acinetobacter baumanii</i> Isolates in Four Health Facilities in Cameroon

Cécile Ingrid Djuikoue, Benhamed Nadjia, Paule Dana Djouela Djoulako, Celianthe Guegang, Cedric Seugnou Nana, Hélène Valérie Same Njanjo, Yemina Grace Kombeu, Christiane Kiyang Possi, Rodrigue Kamga Wouambo, Gandhi Ndieffouo Fosso, Merimé Joel Tchinda Talokou, Bianca Tchounga Chimi, Olivier Pomte, Agbor Michael, Benjamin D. Thumamo Pokam, Nicolas Antoine-Moussiaux
{"title":"Phenotypic Characterization and Prevalence of Carbapenemase-Producing <i>Acinetobacter baumanii</i> Isolates in Four Health Facilities in Cameroon","authors":"Cécile Ingrid Djuikoue, Benhamed Nadjia, Paule Dana Djouela Djoulako, Celianthe Guegang, Cedric Seugnou Nana, Hélène Valérie Same Njanjo, Yemina Grace Kombeu, Christiane Kiyang Possi, Rodrigue Kamga Wouambo, Gandhi Ndieffouo Fosso, Merimé Joel Tchinda Talokou, Bianca Tchounga Chimi, Olivier Pomte, Agbor Michael, Benjamin D. Thumamo Pokam, Nicolas Antoine-Moussiaux","doi":"10.4236/ojmm.2023.133019","DOIUrl":null,"url":null,"abstract":"Background and Objective: Nowadays, the clinical utility of carbapenems is threatened by the emergence of resistant bacteria, favored by its increasing use. According to the WHO, Acinetobacter baumannii: nosocomial infection agent, tops the list of priority antibiotic-resistant pathogens, considered to be the riskiest for humans. This study sought to determine the prevalence of carbapenemase-producing Acinetobacter baumannii strains in four health facilities in the Center and Littoral regions of Cameroon and the associated risk factors. Materials and Method: An analytical cross-sectional study was conducted over a six-month period from January to June 2022. All suspicious A. baumanii isolates obtained from pathological samples at the bacteriology laboratory of the different health facilities were systematically collected and re-identified. Re-identification and antimicrobial susceptibility Testing (AST) were performed using the VITEK 2 System and the Kirby-Bauer method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Detection and phenotypic characterization of carbapenemases was performed according to adequate standard procedures. Results: A total of 168/226 clinical isolates of Acinetobacter baumannii were confirmed after re-identification, among which 52.69% derived from male patients, 55.09% from participants aged between 10 - 39 years old, and 46.71% from pus samples. A very high resistance rates to all families of antibiotics was noted, except to colistin (10.2%). 40.12% of these isolates produced carbapenemase, represented by 62.69% of class B and 37.31% of class A. Carbapenemase production was observed only at HMR1, Centre region and at Laquintinie hospital, Littoral region with 53.33% and 50% respectively, even if there is no significant difference (P = 0.81). In addition, frequent hospitalisation was significantly associated to the production of carbapenemase among A. baumanii (Adjusted-OR = 16.53, P-value 0.0001). Conclusion: This study highlighted the emergence of carbapenemase-producing Acinetobacter baumannii which is increasingly growing. Continuous drug-resistant monitoring and preventive measures could help to prevent and curb the dissemination of A. baumanii resistance genes, especially in health settings.","PeriodicalId":19604,"journal":{"name":"Open Journal of Medical Microbiology","volume":"106 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Journal of Medical Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/ojmm.2023.133019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objective: Nowadays, the clinical utility of carbapenems is threatened by the emergence of resistant bacteria, favored by its increasing use. According to the WHO, Acinetobacter baumannii: nosocomial infection agent, tops the list of priority antibiotic-resistant pathogens, considered to be the riskiest for humans. This study sought to determine the prevalence of carbapenemase-producing Acinetobacter baumannii strains in four health facilities in the Center and Littoral regions of Cameroon and the associated risk factors. Materials and Method: An analytical cross-sectional study was conducted over a six-month period from January to June 2022. All suspicious A. baumanii isolates obtained from pathological samples at the bacteriology laboratory of the different health facilities were systematically collected and re-identified. Re-identification and antimicrobial susceptibility Testing (AST) were performed using the VITEK 2 System and the Kirby-Bauer method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Detection and phenotypic characterization of carbapenemases was performed according to adequate standard procedures. Results: A total of 168/226 clinical isolates of Acinetobacter baumannii were confirmed after re-identification, among which 52.69% derived from male patients, 55.09% from participants aged between 10 - 39 years old, and 46.71% from pus samples. A very high resistance rates to all families of antibiotics was noted, except to colistin (10.2%). 40.12% of these isolates produced carbapenemase, represented by 62.69% of class B and 37.31% of class A. Carbapenemase production was observed only at HMR1, Centre region and at Laquintinie hospital, Littoral region with 53.33% and 50% respectively, even if there is no significant difference (P = 0.81). In addition, frequent hospitalisation was significantly associated to the production of carbapenemase among A. baumanii (Adjusted-OR = 16.53, P-value 0.0001). Conclusion: This study highlighted the emergence of carbapenemase-producing Acinetobacter baumannii which is increasingly growing. Continuous drug-resistant monitoring and preventive measures could help to prevent and curb the dissemination of A. baumanii resistance genes, especially in health settings.
产碳青霉烯酶<i>鲍曼不动杆菌</i>喀麦隆四家卫生机构的隔离病例
背景与目的:碳青霉烯类药物的临床应用受到耐药菌的威胁,其应用日益广泛。据世界卫生组织称,鲍曼不动杆菌:医院感染病原体,在优先耐抗生素病原体名单中名列前茅,被认为是对人类最危险的病原体。本研究旨在确定产碳青霉烯酶鲍曼不动杆菌菌株在喀麦隆中部和沿海地区四家卫生机构的流行率及其相关危险因素。材料和方法:在2022年1月至6月的六个月期间进行了一项分析性横断面研究。系统地收集并重新鉴定了从不同卫生设施细菌学实验室的病理样本中获得的所有可疑鲍曼不动杆菌分离株。根据临床和实验室标准协会(CLSI)的指南,使用VITEK 2系统和Kirby-Bauer法进行再鉴定和抗菌药敏试验(AST)。根据适当的标准程序进行碳青霉烯酶的检测和表型表征。结果:经重新鉴定,共分离出168/226株鲍曼不动杆菌临床分离株,其中男性患者占52.69%,年龄在10 ~ 39岁的患者占55.09%,脓液标本占46.71%。除粘菌素(10.2%)外,对所有抗菌药物的耐药率均很高。40.12%的分离株产生碳青霉烯酶,其中B类分离株为62.69%,a类分离株为37.31%。碳青霉烯酶产率仅在中心区HMR1和滨海区laquininie医院分别为53.33%和50%,但差异无统计学意义(P = 0.81)。此外,频繁住院与鲍曼假单胞杆菌中碳青霉烯酶的产生显著相关(调整后or = 16.53, p值0.0001)。结论:本研究强调了产碳青霉烯酶鲍曼不动杆菌的出现,并日益增长。持续的耐药监测和预防措施可以帮助预防和遏制鲍曼不动杆菌耐药基因的传播,特别是在卫生机构。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信